Investigational drugs for hyperuricemia
Hania Shahid1, Jasvinder A Singh
1University of Alabama, Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health , Birmingham, AL , USA +1 205 996 5885 ; +1 205 996 9685 ; Jasvinder.md@gmail.com.
New drugs are in development to better manage hyperuricemia and its complications. These emerging therapies aim for improved serum uric acid control and reduced adverse events compared to existing treatments.
Area of Science:
- Pharmacology
- Nephrology
- Internal Medicine
Background:
- Hyperuricemia prevalence and complications are increasing globally, creating an unmet medical need.
- Existing treatments for hyperuricemia may have limitations in efficacy and tolerability.
Purpose of the Study:
- To review novel agents for hyperuricemia management currently in preclinical and early clinical development.
- To discuss the mechanisms of action and reported results of these new therapeutic candidates.
Main Methods:
- This review systematically analyzes drugs in various phases of clinical trials for hyperuricemia.
- Focus is placed on agents in Phase I, II, and III trials, including their pharmacological targets.
Main Results:
- Ten novel agents are discussed, categorized by trial phase: Phase II/III (arhalofenate, AC201, RDEA drugs including lesinurad, tranilast, ulodesine) and Phase I (levotofisopam, UR1102, KX1151, LC350189, Marine Active).
- Several drugs, including arhalofenate, ulodesine (BCX-4208), and lesinurad, have advanced to or completed Phase II and III trials.
Conclusions:
- Emerging therapies aim to improve serum uric acid control, enhance tolerability, and minimize adverse events, particularly for patients with comorbidities and the elderly.
- Advances in understanding renal urate transporters are driving the development of these new treatment options.
- New medications are expected to significantly improve the management of symptomatic hyperuricemia in the near future.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Urinary Tract Calculi III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Renal Drug Excretion: Tubular Secretion
Phase II Reactions: Glucuronidation
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)